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BACKGROUND: Short-term memory binding (STMB) tests assess conjunctive binding, 
in which participants should remember the integration of features, such as shapes (or 
objects) and colors, forming a unique representation in memory. In this study, we 
investigated two STMB paradigms: Change Detection (CD) and Free Recall (FR). 
OBJECTIVE: To investigate the cognitive profile in the CD and FR tasks of three 
diagnostic groups: cognitively unimpaired (CU), mild cognitive impairment (MCI) and 
Alzheimer's Clinical Syndrome (ACS). In addition, we aimed to calculate and compare 
the accuracy of the CD and FR tasks to identify MCI and ACS. METHODS: Participants 
were 24 CU, 24 MCI and 37 ACS. The cognitive scores of the clinical groups were 
compared using ANOVA and ROC analyses were carried out to verify the accuracy of 
the STMB tasks. RESULTS: In the CD task, CU was different from MCI and ACS (CU 
> MCI = ACS), while in the FR task all groups were different (CU > MCI > ACS). The 
ROC analyses showed an AUC of 0.855 comparing CU with MCI for the CD task and 
0.975 for the FR. The AUC comparing CU and ACS was 0.924 for the CD and 0.973 for 
the FR task. The FR task showed better accuracy to identify MCI patients, and the same 
accuracy to detect ACS. CONCLUSION: The present findings indicate that impairments 
in CD and FR of bound representations are features of the cognitive profiles of MCI and 
ACS patients.  
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• The accuracy to detect mild cognitive impairment and Alzheimer’s clinical 
syndrome of two modalities of the short-term memory binding test were compared 
• Results indicated that both modalities of the short-term memory binding test 
showed high accuracy to identify these syndromes 




Memory binding refers to the ability to integrate features, such as shape and color, to form 
one unique representational object. The Short-Term Memory Binding (STMB) test1–3 has 
been shown to discriminate patients with Alzheimer’s disease (AD) from cognitively 
unimpaired controls (CU)3–6 and from other dementia sub-types1,2. The STMB tests assess 
conjunctive binding, in which participants should remember the integration of features, 
forming a unified representation in memory.  
Evidence suggests that conjunctive binding is not affected by age7–12 or repeated testing13. 
These properties match those  suggested a good cognitive marker for AD should hold14. 
There are two main paradigms to assess conjunctive STMB. One is the Free Recall (FR) 
task, in which participants retrieve verbally by saying aloud objects and colors 
individually (Unbound Features) or object-color integrations (Bound Features) that they 
have just seen. The other paradigm is the Change Detection (CD) task, in which 
participants recognize if there is a difference in shapes and colors individually or shape-
color integrations between two consecutive screens. Therefore, the CD task relies on 
recognition of abstract shapes, whereas the FR task relies on free recall of common 
objects. The two tasks have proved successful in distinguishing healthy older adults from 
patients with dementia of the Alzheimer’s type1–4,15. However, the CD but not the FR task 
has been used to assess patients with mild cognitive impairment (MCI) showing good 
discriminative power16,17. 
MCI has been described as a heterogeneous syndrome which may represent an 
intermediate stage between normal cognition and dementia18,19. The prevalence of MCI 
in those older than 65 years ranges from 16 to 20% 20. Previous criteria define MCI as a 
condition leading to complaints about cognition (from patient or relatives), measurable 
impairments in one or more cognitive functions, and still preserved abilities to perform 
everyday tasks independently21,22. It is well established that MCI patients have a higher 
risk to convert to dementia, either AD or other types 23,24. Besides, MCI patients could 
revert to cognitive normality20,25,26, especially those who do not show biomarkers of AD 
pathology26,27. It is therefore essential to identify cognitive phenotypes of MCI which will 
accurately predict clinical trajectories. 
For more than a decade, impairment on neuropsychological tests has been used as the key 
criteria to diagnose MCI, but traditional tests do not provide a reliable measure of 
underlying AD pathology. Presently, it is necessary to refine neuropsychological tools to 
better identify patients with the MCI profile who have a higher chance of having positive 
biomarkers and converting to AD dementia. According to a new biological framework to 
diagnose AD, MCI is the intermediate stage in the cognitive continuum between the 
cognitively unimpaired (CU) and patients with dementia, which may or may not have 
AD, depending on biomarker status. This biological framework proposes that AD should 
be identified by in vivo biomarkers, specifically, beta amyloid deposition, pathologic tau, 
and neurodegeneration [AT(N)]28–30. Beta amyloid deposition and pathologic tau are 
required for the diagnosis. Importantly, neurodegeneration and cognitive impairment are 
seen as unspecific symptoms and, therefore, are indicated for staging cognitive 
syndromes.  
Notwithstanding the impact that the AT(N) framework can make to improve 
understanding of AD pathology and selection of candidates for prevention trials, it holds 
several limitations. Relevant to this study are their low specificity for the clinical stage of 
patients, high cost, limited availability, lack of standardization, and need of advanced 
training for use and interpretation14. Therefore, novel cognitive tests that can inform about 
the early stages of AD are still necessary.  New tasks that assess different types of memory 
binding have shown promising results. For instance, Koppara and colleagues (2015) have 
compared CU older adults with participants with subjective cognitive decline (SCD) and 
MCI patients, and they showed that the Bound Features of the CD STMB could 
differentiate SCD and MCI from CU participants16. Another study showed that the CD 
STMB task could differentiate CU volunteers from asymptomatic carriers of the E280A 
single presenilin-1 mutation, a mutation that eventually leads to AD31. In other words, in 
the pre-clinical stage, before cognitive symptoms were present, the asymptomatic carriers 
already showed impairment in conjunctive STMB but unimpaired performance in usual 
neuropsychological tests. Recently, Parra, Calia, García and colleagues (2019) showed 
that MCI patients with hippocampal atrophy in the MRI (probably in the AD continuum) 
had binding deficits similar to those observed in AD dementia patients17. The CD STMB 
test, therefore, seems to be a promising tool to identify AD pre-clinically. Yet, as noted 
above, no study has investigated the usefulness of the FR STMB task to identify patients 
with MCI profile.  
Therefore, the main aim of this study was to contrast the clinical contributions of the two 
modalities of the STMB test. Specifically, the objective was to investigate the cognitive 
profile of three diagnostic groups (CU, syndromal MCI and Alzheimer's Clinical 
Syndrome (ACS)) in the CD and FR STMB tasks. In addition, we aimed to calculate and 
compare the accuracy of the CD and FR tasks to identify syndromal MCI and ACS. The 
comparison of different STMB modalities is novel and hence it may add to our current 
knowledge regarding their vulnerability to and complementary value in the assessment of 




Patients were recruited from Neurology outpatient units from the University of São Paulo 
(USP) and Federal University of Minas Gerais (UFMG). For the CU group, we recruited 
24 older adults from community senior centres and University of Third Age programs. 
To identify the participants with MCI profile, the NIA-AA criteria was used21. Using the 
CU group mean and standard deviation as reference, z-scores were generated for the 
delayed score of the Rey Auditory Verbal Learning Test32. Twenty-one out of 24 (87,5%) 
MCI patients scored < -1.5 SD in this test, therefore were considered as amnestic MCI. 
We recruited 37 patients who met criteria for dementia due to probable AD based on the 
NIA-AA (National Institute on Aging/ Alzheimer’s Association)33. Data collection for 
the study preceded the NIA-AA 2018 biological criteria, and due to the lack of CSF and 
molecular neuroimaging biomarkers, it was not possible to ascertain the presence of AD 
pathology in the sample, therefore, we opted to use Alzheimer's Clinical Syndrome (ACS) 
terminology to describe this group. A sub-sample of the MCI and ACS groups (16 MCI 
and 12 ACS) underwent a structural MRI scan and hippocampal atrophy was used to give 
some support to the diagnostic strategy utilized. 
CU participants, those with MCI profile and caregivers of patients with ACS signed the 
informed consent form, which was approved by the Ethics Committee from USP 





Instruments and procedures 
Participants were assessed by a neurologist and a neuropsychologist. In neurological care, 
patients underwent a clinical evaluation which included the Mini Mental State 
Examination (MMSE)34,35, the Clinical Dementia Rating (CDR)36,37 to assess the 
dementia stage, the Functional Activities Questionnaire (FAQ)38,39 to measure functional 
status and a neuropsychological test battery to assist in the identification of MCI and 
ACS. The latter was comprised of the Dementia Rating Scale (DRS)40,41, the RAVLT32,42, 
and phonemic verbal fluency (FAS)43. The Geriatric Depression Scale (GDS)44 and the 
Hachinski Ischemic Score45 were also applied for screening. 
First, the participants underwent a neurological evaluation conducted by a neurologist 
that, when necessary, could refer to a psychiatric evaluation to exclude mental health 
conditions. Next, all participants completed the neuropsychological assessment. We 
recruited participants aged 55 years and older. All participants had four years of formal 
education or more. For the CU group, inclusion criteria required participants to have 
cognitive scores within the normal range and to be in good self-reported health. The 
exclusion criteria were significant sensory (visual or auditory) or motor deficits and 
severe or decompensated clinical conditions; the CU participants should not have a 
diagnosis of psychiatric or neurologic disorders and use medications with potential 
cognitive side-effects. 
The CU group was defined by the following criteria: MMSE > 24, FAQ < 5, Hachinski 
Ischemic Score ≤ 4, GDS ≤ 5 and anamnesis not indicative of any concurrent condition 
that could affect the central nervous system. For the MCI group the criteria were: MMSE 
> 24, FAQ <5, Hachinski Ischemic Score ≤4, an anamnesis that indicated perception of 
cognitive change in relation to a pre-existing pattern, and impairment in one or more 
cognitive domains (-1.5 SD when compared to normative data). Finally, individuals with 
ACS met the following criteria: MMSE ≤ 24, FAQ ≥5, Hachinski Ischemic Score ≤4, 
impairment in at least two cognitive domains (-1.5 SD when compared to normative data), 
and an anamnesis which should not be indicative of any concurrent condition that could 
affect the central nervous system. After the diagnosis, patients were referred to complete 
the STMB tests.  
The STMB tests took an average of 15 to 20 minutes to be completed. The CD and the 
FR tasks, as well as the Bound and Unbound Features conditions, were counterbalanced 
to avoid order bias. 
 
Change Detection STMB task  
Stimuli were random polygons and non-primary colors previously used7,31. A set of eight 
polygons and eight colors were used to generate the stimuli which were created by 
randomly combining polygons and colors.  
Trials began with a fixation screen for 500 ms after which a study display was presented 
for 2000 ms. The test display was then presented after a 900 ms blank retention interval 
and remained on until the participants responded. On 50% of trials, the study and test 
displays presented identical items. On the other 50%, there were changes between the 
study and test display. The task for the participant was to detect when a change had 
occurred and to respond ‘same’ or ‘different’ as appropriate. There was then a gap of 
1000 ms until the next trial. For the decision of "same or different" the participants were 
clearly informed that they should pay attention only to the items on the screen and not to 
their position as items’ locations changed randomly from study to test. Participants 
performed 16 trials with 2 shapes and 2 colors. 
The task consisted of two conditions, one assesses shapes and colors separately (Unbound 
Features) and the other assesses shapes and colors integrated within objects (Bound 
Features).  
Unbound Features: In this condition, two shapes and two colors were simultaneously 
and separately presented within the same array. No feature was repeated within a given 
display. In the test display for “different” trials, either two shapes (in 50% of the different 
trials) or two colors (in the remaining 50% of the different trials) were replaced by new 
shapes or colors which had not been shown in the study display. Hence, memory for 
bindings of shape and color in the study display was not required to detect a change. 
Bound Features: In this condition, two combinations of shape and color were presented 
for study. No feature was repeated within a given display. In the test display for 
“different” trials, two shapes swapped the colors in which they have been shown in the 
study display. Hence, memory for bindings of shape and color in the study display was 
required in order to detect this change. Figure 1 presents an illustration of the CD task. 
 
INSERT FIGURE 1 HERE 
 
Previous studies7,31 used the shape-only condition, in which participants should detect 
changes in shapes across two consecutives screens. In the present study, we chose to use 
the Unbound condition with colors and shapes unintegrated. The rationale was to use a 
version of the task in which conditions (Bound and Unbound Features) were equated by 
the number of features (as opposed to versions that equated by the number of objects7,31). 
This would also make the baseline condition of the CD task comparable with the baseline 
condition used in the Free Recall task that we explain next.  
 
Free Recall STMB task  
It consisted of displays presenting common objects and primary colors used in previous 
studies1–3. At the beginning of the task, participants were requested to name the colors 
and objects used in the test to ensure that they had no naming problems. 
 
Unbound Features: The study screen consisted of three colors and three objects 
presented as separate features. Half of the items were colored squares and the other half 
were line drawings of common objects. The study screen was presented for 9 seconds in 
total (1.5 sec per feature). Participants were requested to remember as many colors and 
objects as they could. After the study time, they were asked to recall by saying aloud all 
the colors and objects they could remember. Each object and each color correctly recalled 
added one point to the total score. 
 
Bound Features: The study screen consisted of three objects filled with a different color 
each (i.e., colored objects), and it was also presented for 9 seconds (1.5 seconds per 
feature). These colored objects were constructed by randomly combining objects with 
colors from the two sets in a way that avoided prototypical color-object associations (e.g., 
red apple). Participants were asked to remember as many colored objects (combination 
color-object) as possible. We recorded the recalled objects and colors and a response was 
considered correct when the two features making up each studied object were recalled 
together, for instance: “red-bed”.  
Each condition (Bound and Unbound Features) consisted of 6 trials with 6 features each 
(3 colors and 3 objects). Figure 2 presents an illustration of this task. 
 
INSERT FIGURE 2 HERE 
 
Magnetic Resonance Imaging (MRI) Image Acquisition and Processing 
In the present sample, 16 MCI and 12 ACS patients had a recent structural MRI exam 
available (less than six months from the cognitive assessment). Hippocampal volume 
measures from this sample were made available. The images were acquired in a Philips 3 
Tesla scanner with a Quasar Dual gradient system using a 3DT1 weighted turbo-field-
echo gradient sequence with the following parameters: 2500ms repetition time, 3.2 ms 
echo time, 7.0 ms time echo spacing, 900 ms inversion time, 1mm isotropic voxel size, 
8◦ flip angle, 240 × 240 × 160mm3 field of view. 
A healthy control group composed of 133 subjects, from the NKI-RS database (Nathan 
Kline Institute - Rockland Sample) were paired by age with the patients from the Clinical 
Hospital of Ribeirão Preto (USP). For this sample, two types of acquisition were selected, 
the pilot with 2500 ms repetition time, 3.5 ms echo time, 1200 ms inversion time, 1mm 
isotropic voxel size, 8◦ flip angle and 256x256x200mm3 field of view and the enhanced 
with 1900 ms repetition time, 2.5 ms echo time, 900 ms inversion time, 1mm isotropic 
voxel size, 9◦ flip angle and 250x250x176mm3 field of view. 
Volumetric measures of hippocampus were obtained using the FreeSurfer imaging 
software, version 5.3 (Martinos Center for Biomedical Imaging, Charlestown, 
Massachusetts, USA). This software classifies each voxel with a neuroanatomical label 
based on probabilistic information automatically estimated and it has accuracy 
comparable to manual labelling46. This software has been more recently validated in 
elderly subjects, who showed that FreeSurfer volumetry has quality near manual 
editing47. All automatic segmentations were double checked by visual inspection. 
Volumetric measures were normalized by ICV, intracranial volume obtained from 
FreeSurfer pipeline processing, and multiplied by 100 to express as a percentage value. 
 
Statistical Analyses 
The group means of the cognitive measures were compared using one-way ANOVA 
analyses, with Bonferroni’s correction for multiple comparisons. A 3 x 2 mixed ANOVA 
model was used to verify the interactions between the diagnostic groups, as a between-
subjects factor, and CD and FR (with Bound and Unbound Features collapsed) as a 
within-subjects factor. The effect size, as informed by partial eta-squared (ƞ2), and power 
by Beta (β), were calculated in these mixed models. To unfold significant interactions, T-
tests and effect sizes (Cohen’s d) were calculated to compare conditions within and across 
groups. Significance level was set at 0.05. To interpret the effect size, the thresholds 
proposed by Cohen (1988) were used (0.2 = small; 0.5 = medium; 0.8 = large). 
In addition, receiver-operating characteristics (ROC) analyses were used to assess the 
diagnostic accuracy (area under the curve - AUC, specificity and sensitivity) of the CD 
and FR STMB Bound Features to differentiate between the clinical groups. ROC curves 
for the CD and the FR Bound tasks were compared using the DeLong’s test.  Analyses 
were carried out in SPSS v.25 and JASP v.0.11.1.0, and the DeLong’s test was run in the 
pROC package (v. 1.15.3) in R49. 
 
Results 
Table 1 presents descriptive statistics across the clinical groups. The groups had 
equivalent age and educational levels. FAQ scores showed that CU and MCI participants 
had statistically equivalent functional performance, and both had better scores than ACS. 
As expected, CU had higher cognitive performance in general, while the ACS group had 
the lowest performance and the MCI group was in between. In addition, the groups 
showed significantly different hippocampal volumes in MRI data (Normative sample > 
MCI > ACS). 
 
INSERT TABLE 1 HERE 
 
INSERT FIGURE 3 HERE 
  
Results for the CD and FR STMB tests are shown in Figure 3 and Table 2. The results of 
the mixed ANOVA models showed a significant main effect of the FR [F(1,79) = 41.144, 
p < 0.001, η2 = 0.342, β = 1.000] and CD [F(1,81) = 20.665, p < 0.001, η2 = 0.203, β = 
0.994] tasks. There was a significant interaction between diagnostic groups and the FR 
conditions (Unbound and Bound Features) [F(2,79) = 3.294, p = 0.042, η2 = 0.077, β = 
0.609], with the pairwise comparisons showing statistically significant difference 
between the three diagnostic groups (CU > MCI > ACS). In addition, there was no 
significant interaction with the CD tasks [F(2,81) = 2.077, p = 0.132, η2 = 0.049, β = 
0.416], with pairwise comparisons showing CU with higher performance than the other 
groups (CU > MCI = ACS). However, the statistical power (β) in both interaction analyses 
was limited.  
Table 2 contains the comparisons between the Bound and Unbound Features within each 
diagnostic group. For the CD task, there was a significant increase from the Unbound to 
the Bound Features condition, with a large effect size in the CU group, while in the MCI 
the effect size was medium, and in the ACS group there was no significant difference and 
a small effect size. In the FR task, all groups showed statistically significant decrease 
between Unbound and Bound Features condition. The effect sizes showed increasing 
values across groups (CU < MCI < ACS) with a medium effect size for the CU and MCI 
groups, and a large effect size for the ACS group.  
 
INSERT TABLE 2 HERE 
  
ROC analyses with data from the Bound Features (Table 3) indicated that both CD and 
FR STMB tasks had high accuracy to distinguish CU from MCI, and CU from ACS. 
However, accuracy was low to separate MCI from ACS. The CD task showed good 
sensitivity, but low specificity for identifying MCI or ACS, while the FR task showed 
high sensitivity and specificity values. 
 
INSERT TABLE 3 HERE 
 
When the AUC to identify MCI or AD using CD or FR Bound Features were compared, 
there was no significant difference between CD for CU x MCI and CU x ACS (p = 0.298) 
and FR for CU x MCI and CU x ACS (p = 0.670). When the AUC for CD was compared 
to the AUC for FR to discriminate CU x MCI, results were significant (p = 0.016), but 
that was not observed for CU x ACS (p = 0.132). There was no significant difference 




The first aim of the present study was to investigate the contribution of STMB tasks to 
the identification of cognitive profiles in a sample of older adults with different cognitive 
status. STMB assessed via CD clearly distinguished between CU and both MCI and ACS, 
but not between the last two groups (CU > MCI = ACS).  STMB assessed via FR showed 
a gradient whereby CU > MCI > ACS. These findings suggest that impairments of STMB 
functions, assessed via FR and CD, can be observed among individuals from pre-
dementia to the dementia stages of the ACS.  
The second aim was to calculate and compare the diagnostic accuracy for the CD and FR 
tasks. The results suggest that the CD and the FR STMB tasks can identify with high 
accuracy those participants with MCI and dementia profiles, according to the syndromal 
staging framework proposed by Jack et al. (2018)30. However, the Bound FR task showed 
significantly higher accuracy than the Bound CD task to detect MCI.   
To our knowledge, this is the first study to report that the FR STMB task can also identify 
significant impairments in MCI patients. Our results using the CD STMB task are in line 
with previous findings16,17, in which the MCI groups showed significantly worse 
performance than CU participants in the CD Bound condition. In addition, our results 
support previous findings which suggested that STMB impairments can be identified in 
ACS using CD and FR1–3,31,50. We now proceed to discuss our key findings in more 
details.  
 
Effects of binding in CD and FR tasks 
As shown in Table 2 and Figure 3, the CD task revealed that the CU group had higher 
performance on the Bound condition with a large effect size when compared to the 
Unbound condition (binding gain). That did not occur among MCI and ACS patients, 
who showed medium and small effect sizes, respectively. The clinical groups did not 
benefit from binding, as the CU did. In the present, study we used a version of the CD 
which equated memory load across conditions according to the number of features. 
Previous studies have argued that such testing conditions allow assessment of the “weak-
object hypothesis” of visual STM capacity. The hypothesis suggests that visual STM is 
limited by both the number of objects and the feature composition of those objects 51. 
Based on this hypothesis, equating conditions by the number of features should result in 
higher performance level for the Bound Features than the Unbound Features condition. 
This would reflect the benefit that feature integration (i.e., binding) would offer to visual 
STM, which would increase its capacity. Contrary to previous CD tasks which have 
focused on the binding cost (when conditions are equated by the number of objects31,52, 
the CD task used in this study allows assessment of the binding gain. Such a gain can be 
experienced if binding functions supporting feature integration are available. Here we 
have demonstrated that impairments of such binding abilities characterise MCI patients 
and those with the ACS. 
In the FR tasks, on the other hand, the Bound Features yielded a drop in performance in 
the three groups (binding cost), with an increasing effect size from CU to ACS. The 
binding cost was significantly larger in ACS patients, in line with previous findings1,2. 
Such binding cost may be explained by the fact that participants needed to freely recall 
each feature and the binding between features. It has been acknowledged that retrieving 
information via recall is more challenging for older adults than via recognition53,54.  
This evidence is novel and further supports the notion that STMB impairments do 
characterise the cognitive profile of ACS regardless of the task used to assess such a 
function. We have demonstrated for the first time that patients at risk of this type of 
dementia and those in the dementing stages of the disease are less able to benefit from 
binding functions, which alleviate memory load via feature integration in recognition 
tasks, and exhibit a greater cost when more taxing retrieval functions are used (i.e., FR). 
 
Diagnostic accuracy analyses for the CD and FR tasks 
The ROC analyses indicated that the CD and the FR Bound Features showed high 
accuracy to identify MCI and ACS, and very low accuracy to discriminate MCI from 
ACS. The FR task showed statistically better accuracy than CD task to diagnose MCI 
patients, but similar accuracy to diagnose ACS. In addition, the FR task showed high 
sensitivity and specificity values, while the CD task showed high sensitivity, but low 
specificity for MCI and ACS. It could be argued that interactions between disease severity 
and memory load could have played a role in this discrepancy. The Bound condition of 
the FR task presented 6 features/3 objects whereas in the CD task it presented 4 features/2 
objects.  
Parra et al. (2019)17 recently investigated optimal settings of STMB CD tasks to detect 
impairments in MCI patients. In their study, they found that a task presenting 2 objects 
was optimal at revealing specific binding deficits in such patients. They noted that such 
specificity decreased when memory load increased seemingly due to a performance drop 
in the control group. They suggested that to identify impairments in patients in the early 
stages of ACS (i.e., pre-symptomatic or early prodromal stages) assessment should 
include 3 items, while for patients in more advanced stages it should include 2 items. The 
background measures from patients studied by Parra and colleagues (2019)17 and those 
assessed here seem to indicate that the former group was in more advanced stages than 
the latter, as informed by the MMSE and functional scales. Parra and colleagues (2019)17 
suggested that to address this potential limitation, a task that combines the two set sizes 
(2 and 3 objects) may be a more feasible approach. Our current data lend support to this 
proposal.  
It is worth noting that at the group level, a subsample of our MCI patients showed reduced 
volume of the hippocampus. Although hippocampal atrophy characterises ACS dementia 
from the early stages, such a finding in MCI does not guarantee that our patients will 
develop such type of dementia30. Longitudinal assessments involving the versions of the 
STMB tasks above suggested (i.e., STMB tasks combining 2 and 3 items) would help 
identify cognitive profiles of MCI patients that will eventually convert to ACS dementia. 
 
Final remarks 
Based on these results, it would be plausible to suggest that STMB tasks can be a useful 
tool to screen for the ACS profile among MCI patients, as they clearly differ from CU. 
The usefulness of such tests as monitoring tools for dementia progression remains less 
clear. For instance, Logie, Parra, and Della Sala (2015)14 suggested that by tailoring task 
difficulty to the changing abilities of affected patients, the STMB tasks may become 
effective to assess progression and response to treatments (see also Parra et al., 201917). 
Although both STMB tasks achieved high level of accuracy in distinguishing MCI and 
ACS patients from UC, they displayed different classification power. The CD task 
discriminated the MCI and ACS group from CU group but could not distinguish between 
the first two. The FR task, however, revealed a graded impairment which followed the 
disease severity. It might be that STMB functions supporting recognition in CD tasks 
decline dramatically in the very early stages of ACS while those supporting FR continue 
to decline as the disease progresses. Should this hypothesis holds true, CD and FR STMB 
may offer tools for early detection and follow up assessment of people embarked on the 
AD continuum.  
A limitation of the current study worth highlighting is the lack of beta-amyloid or tau 
biomarker data, which precluded the possibility of adhering to the new framework 
supporting the biological definition of ACS. However, we analysed the MRI data 
available from sizeable subsamples of our MCI and ACS groups. These analyses showed 
that hippocampal atrophy would be a likely feature of MCI and ACS patients, identified 
via our assessment protocols. In fact, we found that the severity of such atrophy followed 
the disease course (Normative Sample > MCI > ACS). Although deemed non-specific by 
recent consensus30, hippocampal atrophy has been shown to be a predictor of the 
progression from MCI to AD and it is a hallmark of AD dementia30,33,55–57. Taken 
together, the MRI findings coupled with the observed deficits in the neuropsychological 
measures suggested that our MCI patients were likely in the prodromal stages of AD58.  
In sum, present findings indicated that the CD and the FR STMB tasks can identify MCI 
and ACS with adequate accuracy. To test if the STMB is specific to diagnose ACS 
pathology, future studies should verify the relationship between STMB tasks and ACS 
biomarkers (beta amyloid and tau).  
 
Data Availability Statement: Author elects to not share data. 
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Table 1. Sociodemographic, cognitive characteristics and hippocampal volume across 
clinical groups (n=85). 
  
CU 
(n = 24) 
MCI 
(n = 24) 
ACS 
(n = 37) p-value 
Age 67.83(6.06) 70.33(6.89) 71.14(7.58) 0.195 
Education 12.83(4.06) 9.54(5.82) 10.05(5.23) 0.055 
MMSE 28.29(1.16)c 26.64(1.92)c 23.23(3.74)ab <0.001 
CDR† (22, 2, 0, 0)bc (3, 18, 0, 0)ac (0, 15, 20, 1)ab <0.001 
FAQ 1.09(1.51)c 2.71(2.67)c 9.44(5.77)ab <0.001 
FAS 40.67(13.79)bc 27.54(7.59)a 21.15(10.36)a <0.001 
RAVLT (A1-A5) 49.96(7.54)bc 34.71(10.47)ac 24.68(6.14)ab <0.001 
RAVLT Delayed 10.75(2.21)bc 4.96(2.63)ac 1.24(1.66)ab <0.001 
DRS Total 139.86(3.85)bc 130.33(6.55)ac 119.19(9.24)ab <0.001 
HV left‡ 3698.30(414.77)bc 3387.05(537.03)ac 2689.54(378.06)ab <0.001 
Note. Mean (SD). † = Number of participants who scored 0, 0.5, 1.0 and 2.0, respectively, in CDR; the 
proportions of CDR scores were compared using the chi-squared test; p value refers to ANOVA, with 
Bonferroni post hoc comparisons. ‡ to assess the hippocampal volume data, a subsample of 16 MCI and 12 
ACS patients were compared to a normative sample of 133 controls. In the present sample, 16 MCI and 12 
ACS patients had a recent available image, ; CU = Cognitively Unimpaired; MCI = Mild Cognitive 
Impairment; ACS = Alzheimer's Clinical Syndrome; MMSE = Mini Mental State Examination; DRS = 
Dementia Rating Scale; FAQ = Functional Activities Questionnaire; FAS = phonemic verbal fluency task; 
RAVLT = Rey Auditory Verbal Learning Test; RAVLT (A1-A5) = sum of the first five trials of the 
RAVLT; HV = Hippocampal volume (left hemisphere) taken from the subsample described above. a = 
differ from CU (p < 0.05); b = differ from MCI (p < 0.05); c = differ from ACS (p < 0.05). There were 
missing cases for MMSE (2 in MCI group and 2 in ACS), FAS (4 cases in ACS group), CDR (3 cases for 










Table 2. Results for the comparisons between the Unbound and Bound Features across 
diagnostic groups. 
  CD Unbound CD Bound p-value 
Effect 
Size FR Unbound FR Bound p-value 
Effect 
Size 
CU 84.38(10.43) 96.47(4.92) <0.001 0.989 86.69(8.71) 82.54(7.91) 0.040 0.480 
MCI 71.09(11.48) 78.13(15.20) 0.047 0.428 64.81(12.99) 53.94(13.36) 0.005 0.631 
ACS 68.24(12.70) 71.96(16.45) 0.146 0.244 55.33(16.81) 40.69(20.33) <0.001 1.102 
Note. CU = Cognitively Unimpaired; MCI = Mild Cognitive Impairment; ACS = Alzheimer's Clinical 
Syndrome. CD = Change Detection; FR = Free Recall. Effect Size was calculated using the Cohen’s d 
method. There were three missing cases for FR bound and one for CD bound, both in the CU group. 


















Table 3. ROC analyses for the diagnostic accuracy of the short-term memory binding 
tasks 
Variable Groups Cut off (%) AUC 95% CI Sensitivity Specificity p-value 
CD Bound 
CU x MCI 90.63 0.855 0.741 – 0.970 0.900 0.708 <0.001 
CU x ACS 90.63 0.924 0.858 – 0.991 0.900 0.784 <0.001 
MCI x ACS 71.88 0.612 0.469 – 0.755 0.625 0.514 0.142 
FR Bound 
CU x MCI 75.00 0.975 0.937 – 1.000 0.905 0.958 <0.001 
CU x ACS 75.00 0.973 0.939 – 1.000 0.900 0.919 <0.001 
MCI x ACS 47.22 0.697 0.567 – 0.827 0.667 0.676 0.010 
Note. CD = Change Detection task; FR = Free Recall task; CU = Cognitively Unimpaired; MCI = Mild 
Cognitive Impairment; ACS = Alzheimer's Clinical Syndrome; AUC = Area Under the Curve; CI = 




















Figure 1. Change Detection short-term memory binding test (Unbound and Bound 
Features) 
 
Figure 2. Free Recall Short-term Memory Binding Task (Unbound and Bound Features) 
 
Figure 3. Change Detection (CD) and Free Recall (FR) modalities of the short-term 
memory binding test. CU = Cognitively Unimpaired; MCI = Mild Cognitive Impairment; 
ACS = Alzheimer's Clinical Syndrome. Error bars = SEM. 
